Therapy · 2006 · 39 citations · 79 references
MedicineOncologyPharmacologyCancer ImmunologyChemotherapyMedical OncologyCancer ImmunotherapyLung Cancer PharmacotherapyMetastatic Cancer ManagementMetastatic Disease TreatmentSupportive Care In CancerToxicity ManagementBone Marrow Suppression ManagementGemcitabine-based TherapyLiver Metastases ManagementLiver Metastases TreatmentLung Cancer ResectionPartial Response AssessmentSide Effect Profile
A 65-year-old male with liver metastases after lung cancer resection was treated with five courses of chemotherapy consisting of gemcitabine (GEM) 1,000 mg/m2 (day 1, 8, every 4 weeks) plus carboplatin (CBDCA) AUC 6 (day 1, every 4 weeks). A partial response (PR) was achieved, his symptoms abated and his quality of life(QOL) improved. Although bone marrow suppression was observed as a side effect, it was within the tolerable range and did not interfere with therapy. This approach may be worth considering as a first-line anti-cancer chemotherapy for recurrence lung cancer.
79